Viveve Medical, Inc. VIVE
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 2.38% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.38% | -- | -- | -- | -- |
| Cost of Revenue | -0.90% | -- | -- | -- | -- |
| Gross Profit | 23.24% | -- | -- | -- | -- |
| SG&A Expenses | 7.02% | -- | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.32% | -- | -- | -- | -- |
| Operating Income | -6.30% | -- | -- | -- | -- |
| Income Before Tax | -12.39% | -- | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.39% | -- | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -13.33% | -- | -- | -- | -- |
| Net Income | -12.39% | -- | -- | -- | -- |
| EBIT | -6.30% | -- | -- | -- | -- |
| EBITDA | -8.89% | -- | -- | -- | -- |
| EPS Basic | 43.08% | -- | -- | -- | -- |
| Normalized Basic EPS | 46.09% | -- | -- | -- | -- |
| EPS Diluted | 43.08% | -- | -- | -- | -- |
| Normalized Diluted EPS | 46.09% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 33.34% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 33.34% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |